Want to become a CAPA member? Click here to sign on.

Drug Approval and Patient Input Submissions

The drug development and approval process can be difficult to understand - you can watch this short video here to learn more about it. Underneath the video is more information about how CAPA uses its voice to tell policy-makers why access to approved drugs is important for all arthritis patients.

The Canadian Agency for Drugs and Technologies in Health (CADTH) is an independent, not for profit agency that is funded by Canada’s federal, provincial, and territorial governments, and which provides evidence-based information to health care leaders and policy makers about the effectiveness and efficiency of health technologies (i.e. drugs and medical devices). All new drugs and medical devices that are approved in Canada undergo a CADTH review, which is a process that also calls for input from patient groups. In the case of drugs, this is called the Common Drug Review or CDR. CAPA believes it is important to provide CDR input on all arthritis-related drugs so that there are many options available for people who live with arthritis. When CAPA undertakes submissions to CADTH's CDR, it tries to ensure that voices and experiences of those patients who have used the drug under review are heard.

To learn more about the process of the CADTH CDR, including all stakeholders who provide input to CADTH, see the infographics on CADTH's website here.

CAPA developed and presented a poster presentation for the 2015 CADTH Symposium. The poster highlighted our involvement in providing patient evidence submissions to the CDR process. 

CAPA is in the process of posting its CADTH submissions below, and if you would like your voice heard in the patient input submission process, please visit CAPA's Facebook page for more information on how to contribute to current submissions that are underway.

Note that Ontario and Quebec also have a patient input submission process to which CAPA also provides input - and our submissions to those calls are below the CADTH submissions.

Submissions to CADTH

Click on the titles below to see the submissions CAPA has prepared and submitted to CADTH.

Input on CADTH's patient input template for subsequent entry biologics

Input on conventional synthetic disease-modifying anti-rheumatic drugs (csDMARD's)

Input on availability and access to non-pharmacological treatments for chronic non-cancer pain

Actemra (Tocilizumab) subcutaneous for Rheumatoid Arthritis

Baricitinib for Rheumatoid Arthritis

Canakinumab for Systemic Juvenile Idopathic Arthritis (SJIA)

Cosentyx (Secukinumab) for Ankylosing Spondylitis

Cosentyx (Secukinumab) for Psoriatic Arthritis

Cimzia for Ankylosing Spondylitis

Inflectra (Infliximab) for Ankylosing Spondylitis

Inflectra (Infliximab) for Psoriatic Arthritis

Inflectra (Infliximab) for Rheumatoid Arthritis

Ixekizumab for Psoriatic Arthritis

Nucynta for treatment of pain

TBC (Etanercept) for Ankylosing Spondylitis

TBC (Etanercept) for Rheumatoid Arthritis

Remsima (Infliximab) for Ankylosing Spondylitis

Remsima (Infliximab) for Psoriatic Arthritis

Remsima (Infliximab) for Rheumatoid Arthritis

Sarilumab for Rheumatoid Arthritis

Tofacitinib (Xeljanz) for Psoriatic Arthritis

Xeljanz (Tofacitinib) for Rheumatoid Arthritis

Patient Perspectives of 2017 Symposium 

Submissions to Ontario and Quebec and BC

OPDP Actemra (self-injectable) for Rheumatoid Arthritis

OPDP Apremilast (Otezla) for Psoriatic Arthritis

OPDP Cimzia for Psoriatic Arthritis

OPDP Cimzia for Ankylosing Spondylitis

OPDP Inflectra (Infliximab) for Ankylosing Spondylitis

OPDP Inflectra (Infliximab) for Psoriatic Arthritis

OPDP Inflectra (Infliximab) for Rheumatoid Arthritis

Note that CAPA has provided submissions to BC Pharmacare through their online program for:

Cimzia - Psoriatic Arthritis and Ankylosing Spondylitis

Cosentyx - Ankylosing Spondylitis

Xeljanz - Rheumatoid Arthritis

^ Back to Top